Degarelix Proves to be the Superior Hormone Deprivation Treatment (ADT) for Men with Advanced Prostate Cancer

Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events. The six analyses compared data from randomized trials that [...]

Parenteral Estrogen May Reduce Hormone Agonist Toxicity in Advanced Prostate Cancer

First, I must apologize for having ignored the blog over the last two weeks. I have been intensely focused on the launch of a new project that we at Malecare have been developing. It has managed to take up every available second of my time. At this moment, I am not able to describe much [...]

The Name of The Game Is Life Extension

Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]

Go to Top